Mural Oncology
MA - WalthamBiotechnology
Focus: Mural Oncology is a Waltham, MA-based immunotherapy biotech focused on oncology with a pipeline of early-stage programs targeting advanced solid tumors and hematologic malignancies. The company operates as a pre-revenue stage biotech with multiple clinical-stage assets in development.
Profile data last refreshed 51m ago · AI intelligence enriched 2mo ago
Open Jobs
15+15 this month
Growing — net +15 jobs in 30d
18 jobs added vs 3 removed. Steady team buildout.
Should You Work at Mural Oncology?
AI assessmentMural Oncology presents a high-risk, high-reward early-stage play suitable only for candidates with strong conviction in the science, tolerance for uncertainty, and ability to bootstrap teams with minimal hiring.
Why Work Here
- Pipeline includes Phase 3 combination trial (Nemvaleukin + Pembrolizumab in platinum-resistant ovarian cancer), offering near-term catalysts and clinical validation opportunity
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ALKS 4230
Advanced Solid TumorsClinical Trials (1)
NCT03861793A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Phase 1/2Help build intelligence for Mural Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.